- Investing Ideas
- Hong Kong Pharmaceuticals & Biotech Profitable Climbers
Hong Kong Pharmaceuticals & Biotech Profitable Climbers
Results
7
7 companies
WuXi XDC Cayman
Market Cap: HK$81.2b
An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.
2268
HK$64.55
7D
-0.7%
1Y
90.7%
Biocytogen Pharmaceuticals (Beijing)
Market Cap: HK$32.7b
A biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally.
2315
HK$49.82
7D
-2.2%
1Y
522.8%
JBM (Healthcare)
Market Cap: HK$2.3b
An investment holding company, engages in the manufacture, marketing, distribution, and sale of branded healthcare and wellness products in Hong Kong, Macau, Mainland China, and internationally.
2161
HK$2.76
7D
-1.1%
1Y
46.8%
Innovent Biologics
Market Cap: HK$153.7b
A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally.
1801
HK$88.55
7D
-0.6%
1Y
119.5%
Essex Bio-Technology
Market Cap: HK$2.5b
An investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally.
1061
HK$4.33
7D
-2.7%
1Y
52.5%
Luye Pharma Group
Market Cap: HK$10.6b
Develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally.
2186
HK$2.65
7D
-1.9%
1Y
12.8%
Simcere Pharmaceutical Group
Market Cap: HK$33.6b
An investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China.
2096
HK$12.98
7D
3.0%
1Y
57.1%